|
Market Cap (5-Jun) $19,084,808 (1,108th) |
Close (30-Jun) $0.042 |
Volume (30-Jun) 149,220 |
Shortsold (10-Feb) 15,546 (0.00%) (581st) |
|
52w High $0.059 |
52w Low $0.033 |
P/E 15.29 |
EPS 0 |
RHT released this announcement to the ASX on 24 November 2022, 11:43. The announcement is marked as price sensitive, and is 16 page(s) in length and 6.6MB in size.
You can view all announcements from RHT and see how they appear on a price chart on the announcements page.
At the date of this announcement, RHT was 0.003% short sold according to ASIC data. It was ranked the 581st most shorted stock on the ASX. It remains ranked 581st as of the latest reported data (10 February 2025).
| Other Recent Announcements from RHT | |
|---|---|
| Receipt of R&D Tax Incentive Refund | 30 June 2023, 12:22 |
| Updated HepaFatSmart Cleared by US FDA | 29 June 2023, 11:04 |
| Management Transition | 23 June 2023, 8:18 |
| Investor Presentation | 24 November 2022, 11:43 |
| Resonance Health Contracted for Two New Clinical Trials | 11 November 2022, 8:14 |
| Quarterly Activities/Appendix 4C Cash Flow Report | 31 October 2022, 12:50 |
| Resonance Health Launches Resonance Clinical | 25 October 2022, 11:18 |
You must be logged in to post a reply.
Resonance Health 